What You Should Know:
– ActiGraph, a global leader in wearable digital health technology, announced the acquisition of Biofourmis Connect, a division of Biofourmis specializing in AI-powered digital trial platforms for the life science industry. Financial terms of the acquisition were not disclosed.
– The acquisition combines ActiGraph’s expertise in wearable technology with Biofourmis Connect’s advanced analytics capabilities, creating a comprehensive and unified solution for modernizing clinical research.
Acquisition Impact
The acquisition enables ActiGraph to deliver a market-leading, device-agnostic platform that supports a wide range of clinical use cases throughout the drug development lifecycle. By integrating Biofourmis Connect’s AI-driven technology, ActiGraph enhances its ability to capture and analyze high-precision digital health data, leading to more efficient and patient-centric clinical trials.
“The life science industry has sought out digital innovations to improve clinical development productivity, but they need end-to-end support solidified by operational, analytical, and regulatory expertise. The synergies with Biofourmis Connect will allow ActiGraph to transform its portfolio by adding AI-driven analytics into a digital, device-agnostic platform, allowing our clients to benefit from a true scalable solution with a seamless experience for patients and clinical sites,” said Jeremy Wyatt, CEO of ActiGraph. “We are especially excited to welcome the seasoned Biofourmis Connect employees to our global team, strengthening our capacity for growth and innovation.”
